We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Can-Fite-Completed Patient Enrollment for the Phase II Trial in Psoriasis with CF101

News   Jun 02, 2009

 
Can-Fite-Completed Patient Enrollment for the Phase II Trial in Psoriasis with CF101
 
 
Advertisement
 

RELATED ARTICLES

FDA Grants Fast Track Designation to Onvansertib for Second-line Treatment of KRAS-mutated Colorectal Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

READ MORE

Solving the Medical Mystery of Anesthesia

News

Researchers have solved the longstanding mystery of the mechanisms behind the effects of anesthetics.

READ MORE

New Molecule Stops Drug Cravings in Mice

News

A team from Duke University has developed a synthetic molecule that selectively dampens the physiological rewards of cocaine in mice. This molecule could represent a new class of drugs that may be more specific that currently available medications, with fewer adverse effects.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE